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Fever is a phylogenetically ancient host response to infection, being found in fish and lizards,
and conserved, with all its metabolic costs, in the higher mammals, including man. The
conservation of the fever response in evolution is used as an argument for its survival value and,
indeed, in experiments with cold-blooded animals "behavioral fever" has been demonstrated to
reduce mortality associated with infection. Recent advances in the biology of interleukin-1 and
other cytokines have allowed the testing, in vitro, ofcomponents ofmammalian host defense (such
as immune cell function) at temperatures typical offever, and marked effects have been found. It
remains to be demonstrated, however, that the hyperthermia of fever has survival value in man,
and though it might be predicted that fever would be beneficial in infections, it is quite possible
that in some circumstances even mild fever could be construed as harmful. In autoimmunity, for
example, increased T-cell activation at febrile temperatures may well accelerate disease
progress.
With the heart rate, respiratory rate, and blood pressure, the body temperature of
most hospital patients is recorded at least once daily. The universal recognition of the
value offever as a clinical sign is, ofcourse, ancient [1], and in the past the presence of
fever was often regarded as favorable to the patient's survival prospects. However, in
the late nineteenth century aspirin became available and was greatly used by
physicians who could now relieve their patients of the discomforts associated with
inflammation. Undoubtedly, the popularity ofaspirin derived from pain reduction, the
antipyretic effect being of secondary interest. Nevertheless, the indiscriminate reduc-
tion of fever became common medical practice-the immediate symptomatic gains
apparently outweighing any imponderable risk ofpathogenic penalties.
Interest in the favorable aspects of fever revived in the 1920s with the use of
artificial fever induction to combat intractable chronic infections, but this was soon
overshadowed by the discovery ofantibacterial drugs, although not before curiosity in
the pathogenesis offever and its role in host defense had been aroused.
Today we recognize that fever is a regulated rise in body temperature under central
nervous control [2]. The central nervous adjustments that lead to fever are stimulated
by a pyrogenic polypeptide released from activated host blood or tissue cells such as
macrophages. Originally, the host-derived mediator offever was known as endogenous
or leucocytic pyrogen (EP, LP) [3], and it is nowclear that fever induction is butoneof
many activitiesofendogenous pyrogen [4]. Conversely,othercytokines, ofwhich alpha
interferon is an example, have been shown to possess pyrogenic activity seemingly
independent of EP. Despite this, EP remains the model-ifeventually perhaps not the
only-host mediator offever.
In the 1970s, two key observations in the biology offever were made by contributors
to this symposium: definite survival-valueoffever in infected lizards was demonstrated
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by Kluger and his colleagues [5]; Dinarello and others [6,7] showed that endogenous
pyrogen was probably identical with the immunopotentiating monokine, lymphocyte
activating factor (LAF). This EP/LAF cytokine, now referred to as interleukin-I
(IL-1) was soon credited with a formidable range of biological effects potentially
relevant to host defense and maintenance of tissue structure. Recent gene sequencing
indicates that what we call IL-1 is probably not a single gene product but several
distinct polypeptides derived from a multi-gene family.
These advances have set the stage for a level ofunderstanding ofthe biology of fever
that was hitherto unthinkable. From the clinician's viewpoint, however, it seems that
the role of fever for good or ill in many circumstances will remain unclear at least for
some time to come. In human disease the issue is difficult to resolve for two broad
reasons: first, a direct test ofsurvival value in the whole animal is hard to design since,
in homeotherms, it is impossible to isolate temperature as a single manipulated
variable; second, thevalue ofinformation obtained from applying febrile temperatures
to components of host defense systems in vitro depends on an understanding of their
role in the course ofa particular disease. Clearly, some ostensibly defensive systems-
notably immune responses-may themselves contribute tothe morbidity and mortality
associated with a number of human diseases. The interrelation of fever and immune
cell function is, itself, complicated and merits fuller discussion in this debate.
FEVER AND IMMUNITY
The association offever with the immune response through their shared endogenous
mediator, IL-1, led to the question of how these two effects of IL-1, a brain-mediated
elevation in temperature and augmentation oflymphocyte activation, might be related.
To test ifthe pyrogenic action of IL-I created an optimal temperature environment for
its own lymphostimulatory action, murine thymocytes were exposed to IL-1 both at
370C and at a fever temperature, 390C. T-cell proliferation measured after a three-day
culture was found to be greatly increased at the higher temperature-often as much as
tenfold [8]. This thermal enhancement ofIL-I-driven T-cell proliferation did not seem
a general property of lymphocyte mitogenesis, since B cells responded less well to the
polyclonal mitogen lipopolysaccharide at the higher temperature. It was confirmed in
vivothat the IL-I used in these experiments was pyrogenic for the mouse strain used as
thymocyte donors [9]. Average mouse temperature rose from 37.20C to 38.590C
(range, 0.4-1.90C) following intravenous injection of IL-1.
These studies were extended to test the effect of febrile temperature on the primary,
in vitro, humoral immune response of murine spleen cells to sheep red blood cells. In
this system a whole population of spleen cells responds to the antigenic stimulus by
generating activated B cells that secrete specific antibody. This occurs under T-cell
control during a five-day culture. Initial experiments showed that the number of
antibody-producing B cells obtained from these cultures could be increased by two- to
twentyfold (average, tenfold) by exposure of the spleen cells to febrile temperatures
[10]. Furthermore, optimal effects occurred with exposure to hyperthermia restricted
to the first 24 hours ofculture, and ifcells were held at 370C for the first 48 hours and
then exposed to hyperthermia for the subsequent three days, no thermal augmentation
was detected.
The immune response studied was the outcome of a series of interactions involving
different lymphocyte populations. Studies with isolated cell populations that were
exposed individually to hyperthermia and then added back to re-constitute the whole
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spleen cell culture demonstrated that the generation of T helper cells was greatly
increased at the higher temperature, while B-cell function was not and T suppressor
generation and function were not influenced [10].
It is noteworthy that T cells are highly sensitive to temperature change from about
32°C-typical of the body periphery-up to deep-body temperature levels that occur
during fever [11].
Themolecular basisofthermallyaugmented T-cell function is still notclear, but it is
of interest that hyperthermic conditions that lead to the appearance of "heat-shock
proteins" [12] or "stress proteins" also stimulate immune function when applied for
one hour at a critical time during the first day of a five-day culture. Conversely,
reversible blocking of protein synthesis during thermal exposure prevents both the
appearance of heat-shock proteins and the subsequent augmentation of immune
function measured five days later [13]. Though thermally enhanced T-cell function
was independent ofany change in accessory cell function brought about by heat-shock
conditions in these experiments, other investigators have reported that monocyte IL-I
production is actually reduced by sustained exposure to fever temperatures, suggesting
a possible negative feedback influence ofIL-I on its own release [14].
The recent finding [15] that recombinant human alpha interferon also had
pyrogenic properties led to the testing in mice of the immunoregulatory and the
antiviral properties of interferon at febrile temperatures. At 390C, interferon com-
pletely blocked the generation ofsuppressor cells in vitro and, in vivo, augmented both
delayed-type hypersensitivity and antibody responses [16]. Additionally, fibroblasts
treated with interferon at febrile temperatures were significantly more resistant to
subsequent viral challenge than those treated with interferon at 370C.
The results of these and similar experiments suggest that fever may have survival
value through increased immune responsiveness at higher temperature. However, it is
important to stress that others have found, for example, that natural killer activity of
human mononuclear cells incubated for 18 hours at 390C was significantly reduced, as
was the production of interleukin-1, interleukin-2, and granulocyte-macrophage
colony-stimulating factor [Dinarello CA: personal communication].
IMMUNITY AND FEVER
Apart from the effects that the hyperthermia of fever may have on the function of
the immune system, it is well established that fever is, itself, generated during the
course of immune responses. In the case of cellular immunity, Atkins et al. [17,18]
have demonstrated that antigen reacts with specifically sensitized lymphocytes,
leading to the release of transferable factors that can stimulate EP production in
mononuclear phagocytes. EP-inducing lymphokines are also released following allo-
geneic responses [19] and lectin stimulation oflymphocytes [20]. Recently, Atkins and
Francis showed that desensitization of hypersensitive guinea pigs is associated with
increased cell-mediated suppressionoflymphokine-stimulated EPrelease [21]. Collec-
tively, these results provide an explanation for the occurrence of fever during
delayed-type hypersensitivity reactions.
While lymphokine-mediated EP release may explain fever during cellular immune
responses, it is thought that antigen:antibody immune complexes are responsible for
the occurrence of fever in humoral immune responses. In naive animals treated with
antiserum, fever occurs following injection of antigen [22], and pre-formed antigen-
antibody complexes are pyrogenic in normal animals [23]. A role for the complement
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system in immune complex fever has also been documented [24]. Work from Atkins's
laboratory has demonstrated directly that immune complexes in antigen excess will
stimulate the release of EP from blood leukocytes in vitro [25]. In this study also, as
shown in Fig. 1, a heat-labile cofactor (presumably complement) was required for this
activity [26]. There is therefore good evidence that both cellular and humoral immune
responses can result in the generation ofEP/IL-1 with the development offever in.the
host.
FEVER IN CLINICAL PRACTICE
Laboratory studies such as those discussed previously do suggest that, in mammals,
mild to moderate fever (up to about 390C) may be protective in cases where increased
T-cell activation would favor the host. Presumably, immune responses to most
infectious pathogens would fall into this category. But even with this limitation it must
be remembered that other aspects of accessory and immune cell function, such as the
production of interleukins, may be inhibited at febrile temperatures. Since IL-1
activities affect a wide range of tissues, and IL-i-induced hyperthermia reduces
subsequent IL-I release, many potentially host-defensive responses might be impaired
over and above the loss of the stimulus for fever. Even if it is accepted that fever
temperatures may have a beneficial effect on the immune response against pathogens,
a significant problem arises when we consider the occurrence of fever in sterile
inflammation. Fever in the absence of detectable infection is a common finding in
clinical practice. For example, in a retrospective study of patients on a coronary care
unit, 51 consecutive patients with myocardial infarction by electrocardiographic and
enzyme-release criteria had a mean temperature of 37.470C on the second day, while
45 consecutive patients from the same unit with chest pain but who did not meet the
criteria of a myocardial infarction had a mean temperature of 36.90C on the second
day after the onset of chest pain [Orpin M, Duff GW: personal observations]. At
present, the pathogenesis of this small but consistent fever following myocardial
damage, like the fever associated with pulmonary embolism and similar conditions, is
unknown. Whether these might be beneficial or detrimental to the patient is impossible
tojudge.
On theother hand, in diseases such assystemiclupus erythematosus and rheumatoid
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arthritis, where there is well-documented evidence of pathogenic autoimmune activa-
tion, it might be expected that the facilitating effect of fever temperature on immune
responsiveness would be harmful. It may ofcourse be argued by those who support a
beneficial role for fever that in cases ofautoimmunity the fever occurs as a result ofthe
breakdown of normal control mechanisms and is therefore not comparable with fever
in the setting of a "normal" host defense system. In response, the view could be
expressed that over the course of evolution host defense systems have become more
complicated andtherefore havemorewaysofgoingwrong-andthatfeverinreptiles is
not comparable to fever in humans.
In crystal-deposition diseases such as gout, fever also occurs and urate crystals have
been shown to stimulate EP release from human monocytes in vitro [28], but it is
difficult to imagine any beneficial role of fever temperature in gout. Perhaps in this
disease fever is the price the host must pay for the biological effects ofIL-I which may
contribute to the containment or removal ofurate crystals in the tissues.
Most physicians take theview that mild fevers are best left alone whilehigher fevers
should be reduced, especially in infants and individuals with known organ impairment.
The more important issue is to define the etiology ofthe fever so that specific therapy,
ifit exists, can be instituted. As far as the human host is concerned, the answer to the
question "Is fever beneficial?" must surely be qualified by the conditions in which
fever occurs. In the words ofRobert Louis Stevenson, "the full truth ofthis odd matter
is what the world has long been looking for" [29].
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